Fineline Cube

Follow:
14422 Articles
IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance
CompanyDeals

IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer
CompanyDrug

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer

Novartis Expands Iptacopan Approval to IgA Nephropathy in China
CompanyDrug

Novartis Expands Iptacopan Approval to IgA Nephropathy in China

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection
CompanyDrug

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection

Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors
CompanyDrug

Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors

DaAnGene Secures NMPA Approval for First HIVDNA Diagnostic Kit
CompanyMedical Device

DaAn Gene Secures NMPA Approval for First HIVDNA Diagnostic Kit

NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight
Policy / Regulatory

NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight

Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines
CompanyDeals

Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines

RemeGen Secures China CDE Approval for Telitacicept in Sjögren’s Syndrome, First Biologic of Its Kind
CompanyDrug

RemeGen Secures China CDE Approval for Telitacicept in Sjögren’s Syndrome, First Biologic of Its Kind

Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a Pembrolizumab Biosimilar
CompanyDrug

Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a Pembrolizumab Biosimilar

Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential
CompanyDrug

Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential

Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio
CompanyDrug

Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio